Optimizing Outcomes in PAH: Evidence, Innovation, and Individualization

To participate in this activity, please:

Log in Sign Up

Advancements in treatment directed by risk stratification and the availability of novel targeted therapy provide new opportunities to improve the health outcomes of patients with pulmonary arterial hypertension (PAH). Jennalyn Mayeux, DNP, FNP-C, and Aaron Waxman, MD, PhD, share their perspectives about the contemporary management of patients with PAH, with reference to recent clinical trials of pathway-specific therapies, the 2022 European Society of Cardiology/European Respiratory Society Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension, and 2024 World Symposium on Pulmonary Hypertension Algorithm for PAH. The faculty also share their thoughts about providing personalized care by an interprofessional, multidisciplinary team.

Please visit our related course,  Interprofessional Care of Patients with Pulmonary Arterial Hypertension, by clicking here.

Course Credit:

0.75 AAPA Category I CME Credit
0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours

Dates:

Opens: 2025-10-31
Closes: 2026-10-31

Target Audience:

This activity was developed for a national audience of pulmonologists, pulmonary arterial hypertension (PAH) specialists, advanced practitioners, cardiologists, pharmacists, and other clinicians involved in diagnosis and treatment of patients with PAH.

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 hours AAPA Category 1 CME credits. Approval is valid until October 31, 2026. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Lauren Mangan, PharmD, BCCCP (Medical Writer)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jennalyn D. Mayeux, DNP, FNP-C headshot

    Jennalyn D. Mayeux, DNP, FNP-C

    Nurse Practitioner
    Pulmonary Hypertension & Dyspnea Program
    University of Utah
    Salt Lake City, Utah

  • Aaron B. Waxman, MD, PhD headshot

    Aaron B. Waxman, MD, PhD

    Associate Professor of Medicine
    Harvard Medical School
    Director, Pulmonary Vascular Disease Program
    Brigham and Women’s Hospital
    Boston, Massachusetts

Learning Objectives

  • Describe the pathophysiologic changes associated with disease progression of PAH
  • Conduct a diagnostic evaluation for suspected PAH consistent with current guidelines
  • Construct an individualized PAH care plan using guideline-recommended risk stratification and patient-specific treatment goals
  • Review the safety and efficacy of novel pharmacotherapies for use as treatment escalation in PAH

Faculty Disclosures

Jennalyn D. Mayeux, DNP, FNP-C

Advisory Board: Gossamer Bio, Liquidia

Consultant: Gossamer Bio, Johnson & Johnson, Merck

Speakers Bureau: Johnson & Johnson, Liquidia, Merck, United Therapeutics


Aaron B. Waxman, MD, PhD

Consultant: Merck, OrphAI, Tectonic, United Therapeutics

Data Monitoring Safety Board: INSMED